Nicolai Haase1, Jørn Wetterslev, Per Winkel, Anders Perner. 1. Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen, Denmark, nicolai.rosenkrantz.segelcke.haase@regionh.dk.
Abstract
PURPOSE: We aimed to characterize the degree and clinical importance of bleeding in patients treated withhydroxyethyl starch (HES). METHODS: In post hoc analyses, we examined the associations between fluid assignment, hemostatic variables, bleeding events, transfusions, and death among 798 patients with severe sepsis randomized tofluid resuscitation with HES 130/0.42 versus Ringer's acetate. We used Cox regression analysis adjusted for fluid assignment and baseline characteristics. RESULTS: Overall, 93 (23 %) patients assigned to HES versus 60 (15 %) patients assigned to Ringer's acetate bled in the ICU (relative risk (RR) 1.55; 95 % CI 1.16-2.08; P = 0.003). Of these, 38 and 25 (RR 1.52; 95 % CI 0.94-2.48; P = 0.09), respectively, had severe bleeding (intracranial or concomitant transfusion with three units of red blood cells). Most patients bled in the first days after randomization when most trial fluid was given. The hazards ratios for occurrence of any bleeding and severe bleeding in patients treated withHES versus Ringer's acetate were 1.70 (95 % CI 1.23-2.36; P = 0.001) and 1.55 (95 % CI 0.93-2.56; P = 0.09), respectively. The adjusted hazard ratios for death among patients with any bleeding and severe bleeding compared to those without bleeding were 1.36 (95 % CI 1.04-1.79; P = 0.03) and 1.74 (95 % CI 1.20-2.53; P = 0.004), respectively. CONCLUSIONS: In post hoc analyses of patient with severe sepsis, treatment with HES increased the risk of bleeding which was associated with increased risk of death. HES-induced bleeding complications may negatively affect outcome in patients with severe sepsis.
RCT Entities:
PURPOSE: We aimed to characterize the degree and clinical importance of bleeding in patients treated with hydroxyethyl starch (HES). METHODS: In post hoc analyses, we examined the associations between fluid assignment, hemostatic variables, bleeding events, transfusions, and death among 798 patients with severe sepsis randomized to fluid resuscitation with HES 130/0.42 versus Ringer's acetate. We used Cox regression analysis adjusted for fluid assignment and baseline characteristics. RESULTS: Overall, 93 (23 %) patients assigned to HES versus 60 (15 %) patients assigned to Ringer's acetate bled in the ICU (relative risk (RR) 1.55; 95 % CI 1.16-2.08; P = 0.003). Of these, 38 and 25 (RR 1.52; 95 % CI 0.94-2.48; P = 0.09), respectively, had severe bleeding (intracranial or concomitant transfusion with three units of red blood cells). Most patients bled in the first days after randomization when most trial fluid was given. The hazards ratios for occurrence of any bleeding and severe bleeding in patients treated with HES versus Ringer's acetate were 1.70 (95 % CI 1.23-2.36; P = 0.001) and 1.55 (95 % CI 0.93-2.56; P = 0.09), respectively. The adjusted hazard ratios for death among patients with any bleeding and severe bleeding compared to those without bleeding were 1.36 (95 % CI 1.04-1.79; P = 0.03) and 1.74 (95 % CI 1.20-2.53; P = 0.004), respectively. CONCLUSIONS: In post hoc analyses of patient with severe sepsis, treatment with HES increased the risk of bleeding which was associated with increased risk of death. HES-induced bleeding complications may negatively affect outcome in patients with severe sepsis.
Authors: Ryan Zarychanski; Ahmed M Abou-Setta; Alexis F Turgeon; Brett L Houston; Lauralyn McIntyre; John C Marshall; Dean A Fergusson Journal: JAMA Date: 2013-02-20 Impact factor: 56.272
Authors: John A Myburgh; Simon Finfer; Rinaldo Bellomo; Laurent Billot; Alan Cass; David Gattas; Parisa Glass; Jeffrey Lipman; Bette Liu; Colin McArthur; Shay McGuinness; Dorrilyn Rajbhandari; Colman B Taylor; Steven A R Webb Journal: N Engl J Med Date: 2012-10-17 Impact factor: 91.245
Authors: Bertrand Guidet; Olivier Martinet; Thierry Boulain; Francois Philippart; Jean François Poussel; Julien Maizel; Xavier Forceville; Marc Feissel; Michel Hasselmann; Alexandra Heininger; Hugo Van Aken Journal: Crit Care Date: 2012-05-24 Impact factor: 9.097
Authors: Nicolai Haase; Anders Perner; Louise Inkeri Hennings; Martin Siegemund; Bo Lauridsen; Mik Wetterslev; Jørn Wetterslev Journal: BMJ Date: 2013-02-15
Authors: Simon Finfer; Bette Liu; Colman Taylor; Rinaldo Bellomo; Laurent Billot; Deborah Cook; Bin Du; Colin McArthur; John Myburgh Journal: Crit Care Date: 2010-10-15 Impact factor: 9.097
Authors: Simon J Stanworth; Timothy P Morris; Christine Gaarder; J Carel Goslings; Marc Maegele; Mitchell J Cohen; Thomas C König; Ross A Davenport; Jean-Francois Pittet; Pär I Johansson; Shubha Allard; Tony Johnson; Karim Brohi Journal: Crit Care Date: 2010-12-30 Impact factor: 9.097
Authors: Martin B Madsen; Peter B Hjortrup; Marco B Hansen; Theis Lange; Anna Norrby-Teglund; Ole Hyldegaard; Anders Perner Journal: Intensive Care Med Date: 2017-04-18 Impact factor: 17.440
Authors: Anders Perner; Anthony C Gordon; Derek C Angus; Francois Lamontagne; Flavia Machado; James A Russell; Jean-Francois Timsit; John C Marshall; John Myburgh; Manu Shankar-Hari; Mervyn Singer Journal: Intensive Care Med Date: 2017-05-12 Impact factor: 17.440
Authors: Mette Krag; Anders Perner; Jørn Wetterslev; Matt P Wise; Mark Borthwick; Stepani Bendel; Colin McArthur; Deborah Cook; Niklas Nielsen; Paolo Pelosi; Frederik Keus; Anne Berit Guttormsen; Alma D Moller; Morten Hylander Møller Journal: Intensive Care Med Date: 2015-04-10 Impact factor: 17.440
Authors: Anders Perner; Nicolai Haase; Per Winkel; Anne B Guttormsen; Jyrki Tenhunen; Gudmundur Klemenzson; Rasmus G Müller; Anders Aneman; Jørn Wetterslev Journal: Intensive Care Med Date: 2014-05-08 Impact factor: 17.440
Authors: Sofie L Rygård; Lars B Holst; Jørn Wetterslev; Per Winkel; Pär I Johansson; Jan Wernerman; Anne B Guttormsen; Sari Karlsson; Anders Perner Journal: Intensive Care Med Date: 2016-09-30 Impact factor: 17.440